Diffuse expression of IFNK was seen not only in the epidermis of lesional skin of SLE patients but, more importantly, in the epidermis of non-lesional skin of ANA-positive At-Risk individuals with high IFN activity in blood, who had no clinical or histopathological features of inflammation. This evidence concerns the gene BTG3 and systemic lupus erythematosus.